Education
About Us
Working with TipRanks
Follow Us
Larimar Therapeutics, Inc. (LRMR)
NASDAQ:LRMR
Total Valuation
Larimar Therapeutics has a market cap or net worth of $346.64M. The enterprise value is $81.90M.
Market Cap$346.64M
Enterprise Value$81.90M
Share Statistics
Larimar Therapeutics has 85,590,390 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding85,590,390
Owned by Insiders37.43%
Owned by Institutions9.17%
Financial Efficiency
Larimar Therapeutics’s return on equity (ROE) is -0.47 and return on invested capital (ROIC) is -51.37%.
Return on Equity (ROE)-0.47
Return on Assets (ROA)-0.40
Return on Invested Capital (ROIC)-51.37%
Return on Capital Employed (ROCE)-0.52
Revenue Per Employee0.00
Profits Per Employee-1.24M
Employee Count65
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Larimar Therapeutics is ―. Larimar Therapeutics’s PEG ratio is -0.05.
PE Ratio―
PS Ratio0.00
PB Ratio1.38
Price to Fair Value1.38
Price to FCF-3.33
Price to Operating Cash Flow-2.45
PEG Ratio-0.05
Income Statement
In the last 12 months, Larimar Therapeutics had revenue of 0.00 and earned -80.60M in profits. Earnings per share was -1.32.
Revenue0.00
Gross Profit0.00
Operating Income-90.89M
Pretax Income-80.60M
Net Income-80.60M
EBITDA-90.57M
Earnings Per Share (EPS)-1.32
Cash Flow
In the last 12 months, operating cash flow was -96.49M and capital expenditures -270.00K, giving a free cash flow of -96.76M billion.
Operating Cash Flow-96.49M
Free Cash Flow-96.76M
Free Cash Flow per Share-1.13
Dividends & Yields
Larimar Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.93
52-Week Price Change-16.15%
50-Day Moving Average3.90
200-Day Moving Average3.22
Relative Strength Index (RSI)58.68
Average Volume (3m)1.51M
Important Dates
Larimar Therapeutics upcoming earnings date is Mar 18, 2026, Before Open (Confirmed).
Last Earnings DateNov 5, 2025
Next Earnings DateMar 18, 2026
Ex-Dividend Date―
Financial Position
Larimar Therapeutics as a current ratio of 8.02, with Debt / Equity ratio of 3.85%
Current Ratio8.02
Quick Ratio8.02
Debt to Market Cap0.00
Net Debt to EBITDA0.35
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Larimar Therapeutics has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Larimar Therapeutics EV to EBITDA ratio is -2.60, with an EV/FCF ratio of -2.93.
EV to Sales0.00
EV to EBITDA-2.60
EV to Free Cash Flow-2.93
EV to Operating Cash Flow-2.95
Balance Sheet
Larimar Therapeutics has $175.44M in cash and marketable securities with $4.35M in debt, giving a net cash position of $171.09M billion.
Cash & Marketable Securities$175.44M
Total Debt$4.35M
Net Cash$171.09M
Net Cash Per Share$2.00
Tangible Book Value Per Share$2.80
Margins
Gross margin is -1.66%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin-1.66%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Larimar Therapeutics is $18.00, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$18.00
Price Target Upside344.44% Upside
Analyst ConsensusStrong Buy
Analyst Count9
Revenue Growth Forecast―
EPS Growth Forecast-67.41%